An artificial intelligence model predicts how brain immune cells react to RNA and DNA nanoparticles, helping scientists design safer and more effective nucleic acid therapies faster.
The goal of gene therapy is to permanently cure hereditary diseases. One of the most promising technologies for this is the ...
Outstanding measure of efficacy relative to high-risk cancers with limited treatment options CHICAGO, Oct. 23, 2025 (GLOBE ...
Invited presentation followed by panel discussion on the next wave of innovation in immunotherapy of cancer: Paul Peter Tak, M.D., Ph.D., ...
First five patients in Part C (expansion) of THIO-101 Phase 2 clinical trial enrolled in Taiwan and Turkey CHICAGO, (GLOBE ...
Novel targeted therapies for ARID1A-mutant and CDA-resistant cancers highlighted MENLO PARK, CA / ACCESS Newswire / October 27, 2025 / Edison Oncology, a clinical-stage biopharmaceutical company ...
For more than half a century, Johns Hopkins has been a leader in converting federal support into tangible benefits for the ...
Outstanding measure of efficacy relative to high-risk cancers with limited treatment options CHICAGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) ("MAIA", the "Com ...
Detailed price information for Lantern Pharma Inc (LTRN-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback